Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
Astellas announced 21 abstracts for ESMO 2026 (October 23-27, Madrid), spanning PADCEV plus pembrolizumab in urothelial cancer, VYLOY/zolbetuximab in gastric cancer, and XTANDI in prostate cancer. For Pfizer, the read-through is indirect: PFE earns alliance revenues as a share of U.S. XTANDI profits plus ex-U.S. royalties, and holds PADCEV rights via its December 2023 Seagen acquisition.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.